COMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF EARLY AND DELAYED INITIATION OF COMBINED DRUG THERAPY FOR BPH


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction. Currently, a-blockers (a-AB) and 5-alpha-reductase inhibitors (I-5-AR) are recommended as the drugs of choice for the treatment of patients with benign prostatic hyperplasia (BPH). However, despite the clear advantages of combination therapy, at the initial stages of treatment, I-5-AR is either not prescribed at all, or added to therapy after a few months. The aim of our study is to study the effectiveness of early and various options for delayed combined drug therapy of patients with BPH using a-AB and I-5-AR. Materials and methods. The study included 90 patients with BPH, who were divided into three groups of 30 people. In group 1, monotherapy with drugs from the a-AB group was performed for 6 months, after which they were transferred to treatment with a combined drug. In group 2, monotherapy was performed for three months, after which they were also transferred to treatment with a combined drug. And in group 3, patients were prescribed combination therapy from day 1. Results. Early combination therapy with dutasteride was more effective than delayed Therapy for 6 months. There were no significant differences in the main parameters studied between patients who simultaneously started combination therapy and switched to it after 3 months, by the end of the 12 th month of treatment. However, early therapy is a combined drug made it possible to achieve a more rapid effect in relation to LUTS. Conclusion. Thus, the data obtained confirm the clinical recommendations regarding the expediency of early initiation of combined therapy with an а-adrenoblocker and a 5a-reductase inhibitor in patients with moderate and severe LUTS caused by BPH and the risk of disease progression. Postponing the transition to combination therapy for 6 months or more may lead to a decrease in the effectiveness of treatment of patients in this category.

全文:

受限制的访问

作者简介

A. Kuzmenko

Voronezh State Medical University n.a. N.N. Burdenko

Email: kuzmenkoav09@yandex.ru
MD, professor, Head of Department of Urology

V. Kuzmenko

Voronezh State Medical University n.a. N.N. Burdenko

Email: kuzmenkovv2003@mail.ru
MD, professor at the Department of Urology

T. Gyaurgiev

Voronezh State Medical University n.a. N.N. Burdenko

Email: tima001100@mail.ru
Ph.D., associate professor at the Department of Urology

参考

  1. Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа; 2018. 480 с.
  2. Gravas S., Cornu J.N, Drake M.Jet al. EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2018. Available at: http://uroweb.org/ guideline/treatment-of-non-neurogenic male-luts/ Accessed 5 May 2019.
  3. Аляев Ю.Г., Гаджиева З.К., Рапопорт Л.М., Казилов Ю.Б. Медикаментозное лечение симптомов нижних мочевых путей у мужчин. Роль уроселективности в выборе препарата. Андрология и генитальная хирургия. 2014;1:6-14.
  4. Гаджиева З.К., Казилов Ю.Б. Новые возможности лечения комбинированных симптомов нижних мочевыводящих путей у пациентов с доброкачественной гиперплазией предстательной железы - предпосылки и преимущества. Урология. 2017;1:95-102.
  5. Гаджиева З.К., Аляев Ю.Г., Винаров А.З. Об особенностях выбора медикаментозной терапии при обструктивных заболеваниях нижних мочевыводящих путей. Эффективная фармакотерапия. 2016;41:16-26.
  6. Спивак Л.Г., Локшин К.Л., Винаров А.З. Обзор клинических исследований комбинированной терапии ингибиторами 5а-редуктазы и альфа1-адреноблокаторами пациентов с гиперплазией предстательной железы. Урология. 2015;4:125-133.
  7. Винаров А.З., Спивак Л.Г., Миронов А.В. Комбинированная терапия гиперплазии предстательной железы в свете клинических рекомендаций. Урология. 2017;4:120-128).
  8. Неймарк А.И., Неймарк Б.А., Торбик Д.В. Тактика ведения больного доброкачественной гиперплазией предстательной железы при крупном ее объеме. Бюллетень медицинской науки. 2017;1(5):44-53.
  9. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А., Баранников И.И. Хронобиологический статус больных с хроническим простатитом на фоне аденомы простаты. Системный анализ и управление в биомедицинских системах. 2017;16(3): 513-516.
  10. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Комбинированная медикаментозная терапия больных ДГПЖ. Урология. 2018;1:101-105.
  11. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with Finasteride: metaanalysis of randomized clinical trials. Urology. 1996;48:398-405. doi: 10.1016/s0090-4295(96)00353-6.
  12. McConnell J.D., Bruskewitz R., Walsh P. et al. Proscar Long-term Efficacy and Safety Study The effect of Finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Effcacy and Safety Study Group. N. Engl. J. Med. 1998;338:557-563. Doi: 10.1056/ NEJM199802263380901
  13. Gupta N, Rogers T., Holland B, Helo S., Dynda D, McVary K.T. Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. J Urol. 2018;200(2):405-413. doi: 10.1016/j.juro.2018.02.3088.
  14. Roehrborn C.G, Barkin J, TubaroA, Emberton M, Wilson T.H, Brotherton B.J., Castro R.P. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int. 2014 Apr;113(4):623-635. doi: 10.1111/bju.12500.
  15. Roehrborn C.G, Barkin J, Siami P, Tubaro A, Wilson T.H, Morrill B.B, GagnierR.P. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int. 2011;107(6):946-954. doi: 10.1111/j.1464-410X.2011.10124.x.
  16. Roehrborn C.G., Oyarzabal Perez I., Roos E.P., Calomfirescu N., Brotherton B., Wang F., Palacios J.M., Vasylyev A., Manyak M.J. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with nitiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;7. doi: 10.1111/bju.13033.
  17. Greco K.A., McVary K.T. The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51.
  18. Kozminski M.A., Wei J.T., Nelson J., Kent D.M. Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). BJU Int. 2015;115:308-316 doi: 10.1111/bju.12802.
  19. Dimitropoulos K., Gravas S. Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Ther Adv Urol. 2016;8:19-28. doi: 10.1177/1756287215607419.
  20. D’Agate S., Wilson T., Adalig B, Manyak M., Palacios-Moreno J.M., Chavan C., Oelke M., Roehrborn C., Della Pasqua O. Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms. Br J Clin Pharmacol. 2020. doi: 10.1111/bcp.14268.
  21. D’Agate S., Wilson T., Adalig B., Manyak M., Palacios-Moreno J.M., Chavan C., Oelke M., Roehrborn C., Della Pasqua O. Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH. World J Urol. 2020;38(2):463-472. Doi: 10.1007/ s00345-019-02783-x.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021
##common.cookie##